Literature DB >> 28686113

Effects of different surgical modalities on the clinical outcome of patients with moyamoya disease: a prospective cohort study.

Xiaofeng Deng1,2, Faliang Gao1,2, Dong Zhang1,2, Yan Zhang1,2, Rong Wang1,2, Shuo Wang1,2, Yong Cao1,2, Yuanli Zhao1,2, Yuesong Pan3,4, Xun Ye1,2, Xingju Liu1,2, Qian Zhang1,2, Jia Wang1,2, Ziwen Yang1,2, Meng Zhao1,2, Jizong Zhao1,2.   

Abstract

OBJECTIVE Bypass surgery is the most common treatment for moyamoya disease (MMD), but there is controversy over which surgical modality is best. The objective of this study was to evaluate the clinical outcome of patients with MMD after undergoing different surgical modalities. METHODS A series of 696 consecutive MMD patients treated between June 2009 and May 2015 were screened in this prospective cohort study. Patients who did not undergo revascularization surgeries and those who underwent different surgical modalities in bilateral hemispheres were excluded. Finally, 529 patients who were observed for at least 12 months were included: 438 patients underwent unilateral surgery, and 91 patients underwent bilateral surgery. Of these, 241 patients underwent direct bypass (DB); 81, a combined bypass (CB); and 207, an indirect bypass (IB). Three clinical outcomes were evaluated and compared between surgical groups: recurrent stroke events, modified Rankin Scale (mRS) scores, and change in the main symptoms. RESULTS The mean follow-up period was 40 months. During the follow-up period, recurrent stroke was observed in 43 patients, including 15 patients with hemorrhage, 26 patients with ischemia (transient ischemic attack in 19 patients and infarction in 7 patients), and 2 patients with both hemorrhage and cerebral infarction. Kaplan-Meier analysis showed that patients who underwent a CB or DB had a longer ischemia-free time than those who underwent IB (p = 0.013); however, there was no significant difference in the hemorrhage-free time between the different surgical modalities (p = 0.534). A good neurological status (mRS score ≤ 2) was achieved in 495 patients (93.6%) and was significantly achieved by more children (98.2%) than adults (92.3%; p = 0.022). Surgical modalities were not significantly associated with outcome neurological status (p = 0.860). Moreover, improvement in symptoms was observed in 449 patients (84.9%) and was also significantly more common in children (93.0%) than in adults (82.7%; p = 0.006). No significant difference was observed between the different surgical modalities (p = 0.548). CONCLUSIONS CB and DB are more effective at preventing recurrent ischemic strokes than IB. However, there is no evidence that these 3 surgical modalities demonstrate significant differences in preventing recurrent hemorrhage.

Entities:  

Keywords:  CB = combined bypass; DB = direct bypass; DSA = digital subtraction angiography; EDAS = encephaloduroarteriosynangiosis; IB = indirect bypass; ICH = intracerebral hemorrhage; IVH = intraventricular hemorrhage; MCA = middle cerebral artery; MMD = moyamoya disease; SAH = subarachnoid hemorrhage; STA = superficial temporal artery; TIA = transient ischemic attack; bypass surgery; intracranial hemorrhage; mRS = modified Rankin Scale; moyamoya disease; revascularization; stroke; vascular disorders

Mesh:

Year:  2017        PMID: 28686113     DOI: 10.3171/2016.12.JNS162626

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  19 in total

1.  Predictive factors for acute thrombogenesis occurring immediately after bypass procedure for moyamoya disease.

Authors:  Takeshi Mikami; Hime Suzuki; Ryo Ukai; Katsuya Komatsu; Yukinori Akiyama; Masahiko Wanibuchi; Kiyohiro Houkin; Nobuhiro Mikuni
Journal:  Neurosurg Rev       Date:  2019-02-14       Impact factor: 3.042

2.  Hyperhomocysteinemia is a risk factor for postoperative ischemia in adult patients with moyamoya disease.

Authors:  Junsheng Li; Peicong Ge; Qian Zhang; Fa Lin; Rong Wang; Yan Zhang; Dong Zhang; Wen Wang; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2021-01-27       Impact factor: 3.042

3.  Patients with Moyamoya Vasculopathy Evaluated at a Single-Center in The Netherlands; Clinical Presentation and Outcome.

Authors:  Annick Kronenburg; Rachel Kleinloog; Albert van der Zwan; L Jaap Kappelle; Luca Regli; Kees P J Braun; Catharina J M Klijn
Journal:  J Clin Med       Date:  2021-04-27       Impact factor: 4.241

4.  Multimodal neuronavigation-guided precision bypass in adult ischaemic patients with moyamoya disease: study protocol for a randomised controlled trial.

Authors:  Junlin Lu; Yahui Zhao; Li Ma; Yu Chen; Mingtao Li; Xun Ye; Rong Wang; Xiaolin Chen; Yuanli Zhao
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

5.  Clinical Features, Surgical Treatment, and Long-Term Outcome of a Multicenter Cohort of Pediatric Moyamoya.

Authors:  Jun Zheng; Le-Bao Yu; Ke-Fang Dai; Yan Zhang; Rong Wang; Dong Zhang
Journal:  Front Neurol       Date:  2019-01-22       Impact factor: 4.003

6.  Comparison of Long-Term Effect Between Direct and Indirect Bypass for Pediatric Ischemic-Type Moyamoya Disease: A Propensity Score-Matched Study.

Authors:  Yahui Zhao; Junlin Lu; Shaochen Yu; Jiaxi Li; Xiaofeng Deng; Yan Zhang; Dong Zhang; Rong Wang; Hao Wang; Yuanli Zhao
Journal:  Front Neurol       Date:  2019-07-31       Impact factor: 4.003

7.  Contralateral improvement of cerebrovascular reactivity and TIA frequency after unilateral revascularization surgery in moyamoya vasculopathy.

Authors:  Pieter T Deckers; Wytse van Hoek; Annick Kronenburg; Maqsood Yaqub; Jeroen C W Siero; Alex A Bhogal; Bart N M van Berckel; Albert van der Zwan; Kees P J Braun
Journal:  Neuroimage Clin       Date:  2021-04-21       Impact factor: 4.881

8.  Risk factors for postoperative ischemic complications in pediatric moyamoya disease.

Authors:  Xiaofeng Deng; Peicong Ge; Rong Wang; Dong Zhang; Jizong Zhao; Yan Zhang
Journal:  BMC Neurol       Date:  2021-06-22       Impact factor: 2.474

9.  Use of a panel of four microRNAs in CSF as a predicted biomarker for postoperative neoangiogenesis in moyamoya disease.

Authors:  Gang Wang; Yunyu Wen; Siyuan Chen; Guozhong Zhang; Mingzhou Li; Shichao Zhang; Songtao Qi; Wenfeng Feng
Journal:  CNS Neurosci Ther       Date:  2021-05-04       Impact factor: 5.243

10.  Digital subtraction angiographic characteristics of progression of moyamoya disease 6 months prior to surgical revascularisation.

Authors:  Peicong Ge; Qian Zhang; Xun Ye; Xingju Liu; Xiaofeng Deng; Jia Wang; Rong Wang; Yan Zhang; Dong Zhang; Ji Zong Zhao
Journal:  Stroke Vasc Neurol       Date:  2020-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.